Sign in

    Xin Chen

    Research Analyst at UBS Group AG

    Xin Chen is an Executive Director and Equity Research Analyst at UBS Group AG, specializing in the U.S. biotechnology sector. He covers a range of leading biotech companies including Amgen, Gilead Sciences, Regeneron, and Biogen, and is known for delivering timely and accurate investment insights that have achieved success rates near 70% and above-average returns according to leading analyst ranking platforms. Xin Chen began his career as a research associate at Credit Suisse, later moving to Oppenheimer & Co. before joining UBS in 2016, quickly advancing to his current senior role. He holds FINRA Series 7, 63, and 86/87 licenses, and his analytical acumen and sector expertise have been recognized among top biotechnology analysts on TipRanks.

    Xin Chen's questions to Atour Lifestyle Holdings (ATAT) leadership

    Xin Chen's questions to Atour Lifestyle Holdings (ATAT) leadership • Q4 2024

    Question

    Xin Chen from UBS asked for an update on the strategy for Atour's high-end brands, Atour S and Sakura, and inquired about the recent performance of the Atour Light 3.0 brand.

    Answer

    CEO Haijun Wang stated that the upscale Atour S and Sakura brands are developing in parallel, with the first Sakura hotel in Shanghai receiving high praise since its opening. Regarding Atour Light 3.0, he confirmed its development is aligned with expectations, having expanded to over 100 hotels with strong operational performance and another 100+ in the pipeline, boosting franchisee confidence.

    Ask Fintool Equity Research AI

    Xin Chen's questions to Atour Lifestyle Holdings (ATAT) leadership • Q2 2024

    Question

    Xin Chen from UBS inquired about the company's RevPAR performance trends since July, the outlook for full-year 2024 RevPAR, and the expected full-year profit margin given the shifts in the group's revenue structure.

    Answer

    Founder, Chairman and CEO Haijun Wang acknowledged a high comparison base from last summer but expressed confidence in performance, noting same-hotel RevPAR is expected to outperform the group's blended rate. He raised the full-year revenue growth guidance to a range of 48% to 52% year-over-year and projected the full-year adjusted net profit margin would remain at approximately 18%.

    Ask Fintool Equity Research AI